Lundbeck, a Danish international pharmaceutical company , to acquire Abide Therapeutics, a clinical-stage biopharmaceutical company, for $250m. This acquisition provides Lundbeck a novel discovery platform and a US-based research hub. Dr. Deborah Dunsire, President and CEO of Lundbeck commented: “The acquisition of Abide provides us with a differentiated chemo-proteomic platform to discover new classes of drugs for a broad spectrum of brain diseases starting with those that harness the therapeutic potential of the endocannabinoid system. Abide’s innovative R&D platform provides us with a unique opportunity to strengthen our pipeline now and well into the future, putting Lundbeck in position to deliver multiple new and transformative treatments for brain diseases.”